Michala S SÃ, rensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7239805/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Patient and implant survival following joint replacement because of metastatic bone disease. Monthly Notices of the Royal Astronomical Society: Letters, 2013, 84, 301-306.	3.3	41
2	External Validation and Optimization of the SPRING Model for Prediction of Survival After Surgical Treatment of Bone Metastases of the Extremities. Clinical Orthopaedics and Related Research, 2018, 476, 1591-1599.	1.5	20
3	Use of endoprostheses for proximal femur metastases results in a rapid rehabilitation and low risk of implant failure. A prospective population-based study. Journal of Bone Oncology, 2019, 19, 100264.	2.4	11
4	Longâ€ŧerm results of the Global Modular Replacement System tumor prosthesis for reconstruction after limbâ€sparing bone resections in orthopedic oncologic conditions: Results from a national cohort. Journal of Surgical Oncology, 2019, 120, 183-192.	1.7	10
5	Incidence of surgical interventions for metastatic bone disease in the extremities: a population-based cohort study. Acta Oncológica, 2019, 58, 456-462.	1.8	9
6	Patient survival following joint replacement due to metastatic bone disease – comparison of overall patient and prostheses survival between cohorts treated in two different time-periods. Acta Oncológica, 2018, 57, 839-848.	1.8	8
7	Clinically Important Reductions in Physical Function and Quality of Life in Adults with Tumor Prostheses in the Hip and Knee: A Cross-sectional Study. Clinical Orthopaedics and Related Research, 2021, 479, 2306-2319.	1.5	6
8	Prognostic value of biochemical variables for survival after surgery for metastatic bone disease of the extremities. Journal of Surgical Oncology, 2017, 115, 442-448.	1.7	5
9	Extent of Surgery Does Not Influence 30-Day Mortality in Surgery for Metastatic Bone Disease. Medicine (United States), 2016, 95, e3354.	1.0	4
10	Preoperative BMD does not influence femoral stem subsidence of uncemented THA when the femoral T-score is > –2.5. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 538-543.	3.3	4
11	Clinical outcome after surgery on schwannomas in the extremities. World Journal of Orthopedics, 2021, 12, 760-767.	1.8	3
12	Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities. Cancers, 2021, 13, 2833.	3.7	2
13	Surgical Treatment of Metastatic Bone Disease in the Appendicular Skeleton: A Population-Based Study. Cancers, 2022, 14, 1258.	3.7	2
14	Surgical Treatment of Metastatic Bone Disease—When Decisions at End-of-Life Really Makes the Difference. Cancers, 2021, 13, 2581.	3.7	1
15	Biochemical Variables are Predictive for Patient Survival after Surgery for Skeletal Metastasis. A Prediction Model Development and External Validation Study. The Open Orthopaedics Journal, 2018, 12, 469-481.	0.2	1
16	Response from authors (Sorensen etÂal.). Journal of Bone Oncology, 2020, 22, 100286.	2.4	0
17	Plasma YKL-40 as a biomarker in patients with nonmetastatic bone and soft tissue sarcomas: a prospective exploratory clinical study. International Journal of Surgery Oncology, 2021, 5, 87.	0.2	0
18	Quantitative measurements of adaptive bone remodeling around the cemented Zimmer® segmental stem after tumor resection arthroplasty using dual-energy x-ray absorptiometry. BMC Musculoskeletal Disorders, 2021, 22, 518.	1.9	0